Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360520 | 0.91 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1KDM4EKMT2ATOP2A | |
| SCHEMBL1873160 | 0.87 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1KDM4EKMT2ATDP1 | |
| SCHEMBL5455185 | 0.85 | ALDH1A1 (0.42) | ALDH1A1TDP1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL1515858 | 0.85 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1KDM4EKMT2AGAA | |
| SCHEMBL1880513 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1KDM4EKMT2ATOP2A | |
| SCHEMBL1515913 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ETDP1MAPTSMN1; SMN2 | |
| SCHEMBL360406 | 0.78 | KMT2A (0.45) | ALDH1A1L3MBTL1KDM4EKMT2ATDP1 | |
| SCHEMBL28715368 | 0.78 | CREBBP (0.51) | ALDH1A1KMT2ATDP1GAAMAPT | |
| SCHEMBL11347738 | 0.78 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1KDM4EKMT2ATOP2A | |
| SCHEMBL28410942 | 0.78 | ALDH1A1 (0.59) | ALDH1A1KDM4ETDP1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| US-9067893-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | NIVALIS THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8946434-B2 | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | N30 PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8741915-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2592934-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2480086-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012009227-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011038204-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ALDH1A1 207/4885L3MBTL1 4828/4885KDM4E 3194/4885 |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | QDPR, TACR1, TACR2 | ALDH1A1 751/4885L3MBTL1 4858/4885KDM4E 3492/4885 |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | QDPR, TACR1, TACR2 | ALDH1A1 751/4885L3MBTL1 4858/4885KDM4E 3492/4885 |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ALDH1A1 207/4885L3MBTL1 4828/4885KDM4E 3194/4885 |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ALDH1A1 207/4885L3MBTL1 4828/4885KDM4E 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.